Patient involvement in the design of ALIDHE: a study of ivosidenib plus azacitidine in newly diagnosed IDH1 mutant AML


Por: Nier, S, Pelouchova, J, Hills, R, Salek, S, Derrien, H, Chatin, S, De La Bigne, AM, Vives, S, Recher, C, Döhner, H, Venditti, A and Vyas, P

Publicada: 8 dic 2025 Ahead of Print: 1 nov 2025
Resumen:
Aims: The ALIDHE study aims to supplement previous clinical trial data by evaluating the safety and tolerability of ivosidenib + azacitidine in adult patients with newly diagnosed mutant isocitrate dehydrogenase acute myeloid leukemia (AML). Methods: Notably, this study has been designed in collaboration with patient representatives from the Acute Leukemia Advocates Network (ALAN) at all stages. Patient representatives from ALAN completed a survey and attended workshops to share feedback on the study design to reduce the burden of participation for patients. Using feedback from ALAN, the study protocol was adjusted to minimize clinical visits and optimize study duration. Quality of life and mental health were included as endpoints in ALIDHE as these outcomes have been recognized as important to capture the lived experiences of patients with AML. Efforts were made to ensure patient comprehension through accessible study documents such as a plain language video and one-page summary. Conclusions: ALIDHE represents, to our knowledge, the first AML clinical trial that involves patient representatives from development of the study concept to follow-up. ALAN will continue to be involved in ALIDHE as part of the patient steering committee, to ensure that patient perspectives and needs continue to be considered throughout the study duration.

Filiaciones:
Nier, S:
 Acute Leukemia Advocates Network, Bern, Switzerland

Pelouchova, J:
 Acute Leukemia Advocates Network, Bern, Switzerland

Hills, R:
 Acute Leukemia Advocates Network, Bern, Switzerland

Salek, S:
 Univ Hertfordshire, Sch Life & Med Sci, Hatfield, England

Derrien, H:
 SERVIER, Suresnes, France

Chatin, S:
 SERVIER, Suresnes, France

De La Bigne, AM:
 SERVIER, Suresnes, France

:
 Hosp Germans Trias I Pujol, Hematol Dept, ICO, Badalona, Spain

 Univ Autonoma Barcelona, Jose Carreras Leukemia Res Inst, Barcelona, Spain

Recher, C:
 Univ Toulouse III Paul Sabatier, Toulouse, France

 Canc Res Ctr Toulouse, Toulouse, France

 Ctr Hosp Univ Toulouse, Inst Univ Canc Toulouse Oncopole, Toulouse, France

Döhner, H:
 Ulm Univ Hosp, Dept Internal Med 3, Ulm, Germany

Venditti, A:
 Univ Roma Tor Vergata, Dept Biomed & Prevent, Hematol, Rome, Italy

Vyas, P:
 Univ Oxford, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford, England
ISSN: 14796694





Future Oncology
Editorial
Future Medicine Ltd., UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 21 Número: 29
Páginas: 3713-3719
WOS Id: 001619337200001
ID de PubMed: 41257493
imagen Green Accepted, hybrid

MÉTRICAS